Introduction
Platelet hyper-reactivity is observed in patients after myocardial infarction' and may still be detectable 3 months to 2 years later.2'3 It is likely that platelets play an important part in the pathogenesis of infarction because of their atherogenic properties, by occluding vessels with circulating platelet aggregates or by producing vasoconstricting agents locally.
Two-major trials showed that sulphinpyrazone reduced the incidence of sudden death4 and reinfarction' in the first 6 months after myocardial infarction.
The presentation and interpretation of data in the first of these studies were criticized, but an independent reevaluation of the original material confirmed a favourable trend towards overall survival of patients treated with sulphinpyrazone. 6 The mode of action of the drug in this context is unclear. The suggestion that it has anti-arrhythmic properties was not confirmed by Wilcox et al.7 nor by Kubik (unpublished observations). An anti-platelet action is more likely. Wallis8 has shown that sulphinpyrazone inhibits the enzyme cyclo-oxygenase and prostaglandin synthesis. When given to normal subjects, the drug impairs platelet aggregation induced by arachidonic acid (a prostaglandin precursor) and reduces the synthesis of malondialdehyde (an end product of platelet prostaglandin metabolism). 9 For these reasons, arachidonic acid-induced platelet aggregation and malondialdehyde production were measured serially in the immediate post-infarction period and throughout the first 6 months after myocardial infarction. A double-blind trial of sulphinpyrazone was employed to see if the drug modified platelet behaviour during this period.
Patients and methods
All patients with a presumptive diagnosis of myocardial infarction admitted to the coronary care unit were evaluated for inclusion in the study. Only those in whom peptic ulcer had been diagnosed within the previous 3 years, those with a known hypersensitivity to pyrazole derivatives, those taking anti-platelet or anti-coagulant therapy and those on non-steroidal anti-inflammatory agents within 2 weeks of admission were not considered. Sixty five consecutive patients were accepted in the study. Ten were withdrawn after baseline investigations because they did not meet the inclusion criteria. In three, serial electrocardiograms and cardiac enzyme levels did not confirm myocardial infarction, in five the serum creatinine was raised and in two the serum uric acid was above 0.5 mmol/l. The 55 remaining patients were randomized in double-blind fashion to receive sulphinpyrazone or placebo for 6 months.
In 
Results
Of the 55 patients admitted to the study, 27 received sulphinpyrazone and 28 placebo. The age and sex distribution of the two groups was comparable. The incidence of previous infarction, angina, hypertension, diabetes and smoking habits was similar as was treatment with beta-blockers, diuretics and calcium antagonists (Table I) Time (days) Figure 3 Arachidonic acid induced aggregation response during the first week after myocardial infarction. pyrazone ( Figure 3 ). In both treatment groups, malondialdehyde levels were lower than normal control values at entry into the study and during the first 2 months of treatment. While the mean levels in the sulphinpyrazone group were consistently lower throughout the treatment period, the differences were not statistically significant.
Haemoglobin and red cell values rose steadily in the placebo group during the period of study, but remained stable in the sulphinpyrazone patients. Though the levels were within the normal range, the difference between the two groups became significant at the third month and remained so thereafter without any biochemical evidence of haemolysis, or clinical suspicion of blood loss in the sulphinpyrazone treated patients (Figures 4, 5 ). White cell counts were similar in the two groups.
Serum urea and creatinine were higher during the first 7 days oftreatment in the sulphinpyrazone treated group, though the differences were not statistically significant. Similar changes were also seen in the smaller study group, being apparent on the third day. The uricosuric effect of sulphinpyrazone was reflected by a significant fall in serum urate which was evident by the third day of therapy and which persisted throughout the treatment period. This fall provided a retrospective index ofgood patient compliance confirmed by serum drug assay levels. No patient had to be withdrawn because of an unacceptable deterioration in renal function and no patients complained of any symptoms attributable to sulphinpyrazone.* Discussion Enhanced platelet aggregation to adenosine diphosphate and collagen and increased platelet adhesiveness * The authors will let any interested reader have a copy of the data. Sulphinpyrazone treatment reversed this hyperreactivity to levels near to or within the normal range. The effect became apparent on the third day of treatment and persisted throughout the 6 months of Time (months) Figure 5 Mean red cell count (RCC) levels in sulphinpyrazone and placebo treated patients (P <0.01 at months 2, 3 and 6).
therapy. Re-evaluation one month after the drug was stopped showed a return to the same high level of reactivity as in the untreated patients. Maguire et al.9 demonstrated that sulphinpyrazone reduced the production of malondialdehyde in normal subjects. Such reduction was not apparent in our study of patients after myocardial infarction nor was it observed by Latour et al.3 in patients taking sulphinpyrazone 2 months after infarction.
Ifmalondialdehyde levels, like thromboxane A22 are an indicator of the magnitude of prostaglandin synthesis, high levels would be expected in the post-infarction period. In our study, malondialdehyde production was below normal in treated and untreated patients in the first 2 months after infarction. This may reflect consumption of activated platelets, leaving a population of older less reactive ones, which Frampton et al.20 showed to remain hyper-responsive to arachidonic acid. Alternatively, as Smith et al. ' 2 point out, a decrease in malondialdehyde production may not necessarily result from a decrease in prostaglandin endoperoxide synthesis but be due to increased production of other stable end-products and PGF2.
The steady and significant rise in haemoglobin and red cell count that occurred in the placebo but not in the treatment group remains unexplained. There was no evidence of bone marrow suppression or haemolysis and no clinical suspicion of blood loss. While the haemocrit is a major determinant of whole blood viscosity and hence of blood-flow, it is unlikely that the small difference seen here would modify flow properties and contribute to the beneficial clinical effects of sulphinpyrazone. Our study demonstrates a reversal of platelet hyper-reactivity after a few days' treatment with sulphinpyrazone. This effect was maintained throughout 6 months of treatment and was lost when therapy was withdrawn. The potential in vivo 
